ALLIANCE FOR AGING RESEARCH for ALLIANCE FOR AGING RESEARCH
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Supported the SALSA Act (H.R. 2377 / S. 1000 to stop Congressional cuts to clinical laboratories
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER | — |
| MICHAEL WARD | — |
Health Issues HCR
-For H.R. 485 Protecting Health Care for All Patients Act of 2023, in support of a full federal ban on the use of the Quality Adjusted Life Year -Increase federal funding for domestic and global antimicrobial resistance programs -In support of the President's April 18 Executive Order that advances policies that provide resources to family caregivers and advocate for more federal resources to better support them -In support of the United State's Preventative Services Task Force's effort to reevaluate pharmaceutical interventions for obesity
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER New | — |
| MICHAEL WARD | — |
Medicare/Medicaid MMM
-Lobbied for patient focused approach to the implementation of the Inflation Reduction Act's provisions for an out of pocket cap of $2000 for Medicare beneficiaries and the smoothing of costs for that population -Responded to the Agency's proposed guidance on the direct negotiation provision of the Inflation Reduction Act, advocating for them to avoid using discriminatory metrics like QALYs during the price setting process and asking them to ensure patients were included in those discussions -Responded to an HCPM guidance for implementation of the Part D provisions in the inflation reduction act advocating for patients to have continued access to therapies and for the program to monitor any impacts of direct negotiation on access, as well as recommending best practices for smoothing implementation -Lobbied Congress to have Medicare to create a complimentary measure for their current long-stay antipsychotic measure -Support S. 1544, which directs Medicare to expand access to PET radiopharmaceuticals -Lobbying on Medicare's Alzheimer's disease national coverage determination
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER | — |
| MICHAEL WARD | — |
Budget/Appropriations BUD
-Requested report language to be included in the Labor, Health and Human Services, and Related Agencies FY 24 Bill that would instruct Medicare to create a companion measure to their current antipsychotic use measure in long-term care facilities that would measure appropriate use -Requested report language to be included in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies FY 24 bill that would instruct the FDA to create a path forward for removing the black box label on antipsychotics for older adults
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER | — |
| MICHAEL WARD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.